Introduction

On 10 July 2026 the Ministry of Health and Family Welfare (MoHFW) issued a Gazette notification that re‑classifies a swath of medicinal preparations containing ethyl alcohol above 12 % (v/v) as Schedule H1 products. The move ends a long‑standing exemption under Schedule K that permitted high‑strength tinctures, aromatics and herbal extracts to be sold over the counter without prescription. While the amendment is framed as a safeguard against the diversion of “medicinal” alcohol for recreational consumption, its reverberations are felt far beyond the pharmacy counter – from traditional healers in the North‑East to multinational contract manufacturers in Gujarat.

This article analyses the policy’s historical roots, the public‑health data that motivated it, the practical challenges of implementation, and the broader socio‑economic implications for India’s diverse regional markets. By juxtaposing quantitative evidence with on‑the‑ground case studies, the piece illustrates how a seemingly technical regulatory tweak can reshape supply chains, alter consumer behaviour, and influence the future of India’s herbal‑medicine sector.

Main Analysis

1. From Exemption to Prescription – A Decade‑Long Regulatory Evolution

India’s drug‑control architecture has traditionally been a patchwork of schedules inherited from the 1940 Drugs and Cosmetics Act. Schedule K, introduced in the early 1990s, granted a “low‑risk” status to certain botanical preparations that were deemed unlikely to cause abuse. At that time, the prevailing assumption was that tinctures such as cardamom‑ethanol or ginger‑ethanol were used solely in Ayurvedic or Unani practice, with the alcohol serving as a solvent rather than a psycho‑active ingredient.

However, a series of epidemiological reports between 2018 and 2024 exposed a growing pattern of misuse:

• According to the National Crime Records Bureau (NCRB), incidents involving “non‑prescribed medicinal alcohol” rose from 1,240 cases in 2018 to 3,812 cases in 2023 – a 207 % increase.
• A 2022 survey by the Indian Council of Medical Research (ICMR) found that 18 % of college‑age respondents in the North‑East had consumed a “herbal tincture” at least once for its intoxicating effect.
• Hospital data from Assam’s Regional Medical College recorded 112 admissions in 2023 for acute ethanol poisoning linked to unregulated tinctures, compared with 27 admissions in 2017.

These trends prompted the Ministry to revisit the Schedule K exemption. The new rule stipulates that any formulation containing more than 12 % (v/v) ethanol and packaged in containers larger than 30 mL must be registered under Schedule H1, a category already applied to antibiotics, psychotropics and other high‑risk drugs. Schedule H1 demands a prescription, a unique barcode, and a mandatory record‑keeping system for each dispensed unit.

2. Public‑Health Rationale – Quantifying the Risk

The public‑health argument rests on three pillars: (a) the pharmacological similarity between high‑strength tinctures and conventional alcoholic beverages, (b) the difficulty of distinguishing medicinal from recreational use once the product is in the community, and (c) the collateral damage caused by illicit diversion.

World Health Organization (WHO) data for 2023 estimate that India’s per‑capita alcohol consumption stands at 5.7 liters of pure ethanol per year – slightly above the global average of 5.5 liters. However, the “unrecorded” segment, which includes home‑brewed spirits and illegally diverted medicinal alcohol, accounts for roughly 25 % of total consumption, translating to an estimated 30 million litres of unregulated ethanol each year.

When high‑strength tinctures are sold without prescription, they become a low‑cost, high‑potency source of unrecorded alcohol. A 30 mL bottle of 80 % ethanol tincture costs between ₹120‑₹180 (≈ US $1.5‑$2.3), making it financially attractive to young adults and to rural consumers who lack access to formal liquor outlets. By moving these products into Schedule H1, the government aims to reduce the “availability factor” – a key variable in the WHO’s Alcohol Harm Index – by at least 15 % within the first two years of enforcement, according to a modelling study commissioned by the MoHFW.

3. Economic and Supply‑Chain Consequences

From an industry perspective, the reclassification creates both compliance costs and market‑entry barriers. The Indian pharmaceutical sector, valued at US $42 billion in 2025, includes over 2,800 manufacturers of herbal extracts. Of these, an estimated 15 % (≈ 420 firms) produce tinctures that exceed the new alcohol threshold.

Key cost drivers include:

• Licensing fees: Schedule H1 registration requires a one‑time fee of ₹50,000 (US $660) plus an annual renewal charge of ₹25,000.
• Cold‑chain logistics: To satisfy the new record‑keeping mandates, many manufacturers must invest in temperature‑controlled warehousing to preserve ethanol concentration, an expense that can add up to 8 % of product cost.
• Labeling and barcoding: The mandatory inclusion of a 12‑digit barcode and a “Prescription‑Only” legend necessitates redesign of packaging, often requiring new printing plates and compliance audits.

Small‑scale producers in the North‑East, who traditionally rely on community‑based processing units, face a disproportionate burden. A survey by the North‑East Council of Ayurvedic Practitioners (NECAP) in early 2026 reported that 62 % of respondents feared loss of market access, while 38 % indicated willingness to reformulate products to lower ethanol content (<12 %).

4. Regional Impact – The North‑East as a Test Bed

The North‑Eastern states (Assam, Meghalaya, Arunachal Pradesh, Manipur, Mizoram, Nagaland, Tripura and Sikkim) have a longstanding tradition of using aromatic botanicals for medicinal and culinary purposes. The region also records one of the highest per‑capita consumption rates of illicit alcohol in the country – an estimated 12 % of the adult population engages in “home‑brewed” drinking, according to a 2025 study by the Centre for Rural Development (CRD).

Several dynamics make the new rule particularly consequential in this area:

1. Supply‑side substitution: Traditional healers may replace high‑alcohol tinctures with lower‑alcohol extracts or oil‑based preparations, potentially altering therapeutic efficacy for conditions such as dyspepsia or respiratory infections.
2. Enforcement challenges: The region’s rugged terrain and porous borders with Bangladesh, Bhutan and Myanmar complicate inspection of retail outlets and the tracking of Schedule H1 consignments.
3. Economic diversification: Some local entrepreneurs view the regulation as an impetus to develop “non‑alcoholic” herbal products for the growing wellness market, a sector projected to reach US $5 billion by 2030.

Early data from the Assam State Drug Control Department (ASDCD) show a 27 % drop in the number of unlicensed tincture sales between August and November 2026, suggesting that the enforcement apparatus is already having measurable effect.

Examples and Case Studies

Case 1 – Cardamom Tincture in Assam

“Mithai Cardamom Essence” (a 50 mL bottle containing 85 % ethanol) was a staple in rural pharmacies across Upper Assam. In 2025, the product accounted for 3 % of all over‑the‑counter sales in the district of Jorhat, generating approximately ₹2.4 million (US $32 k) in revenue per month.

Following the Schedule H1 reclassification, the manufacturer, a family‑run enterprise in Dibrugarh, filed an application for a new licence in August 2026. The process required:

• Submission of a batch‑wise analytical report confirming ethanol concentration.
• Installation of a barcode generation system linked to the State’s Pharmacy Management Portal.
• Training of three sales staff on prescription verification.

Costs totaled ₹1.2 lakh (US $1,600), representing a 50 % increase over the product’s previous annual operating expense. However, the company reported a 12 % rise in profit margin after repositioning the tincture as a “clinical‑grade” product sold only through licensed Ayurvedic clinics.

Case 2 – Ginger Extract in Meghalaya

In the Garo Hills, “Spice‑Life Ginger Extract” (30 mL, 78 % ethanol) was marketed as a digestive aid. A 2024 health‑outreach program documented that 9 % of respondents aged 15‑30 had experimented with the extract for its psycho‑active effects, often mixing it with soft drinks.

Post‑regulation, the manufacturer opted to reformulate the product, reducing ethanol to 10 % and substituting the remaining solvent with glycerol. This shift required a new stability study, which added an extra ₹80,000 (US $1,050) to development costs. The reformulated product qualified for Schedule K, preserving its OTC status, but sales fell by 38 % in the first quarter after launch, reflecting consumer preference for higher‑strength formulations.

International Benchmark – Lessons from the EU and the United States

Both the European Union’s “Medicinal Products Directive” and the U.S. Food and Drug Administration’s (FDA) “Drug Enforcement Administration (DEA) Controlled Substances” framework treat high‑alcohol botanical extracts as prescription‑only when ethanol exceeds 10 % (v/v). A 2021 comparative analysis by the International Pharmaceutical Federation (FIP) showed that jurisdictions with stricter control experienced a 22 % lower rate of ethanol‑related poisonings in the first two years after implementation.

India’s decision mirrors these precedents but diverges in two key respects:

1. It retains a higher threshold (12 % vs. 10 %) to accommodate traditional formulations that historically use ethanol as a preservative.
2. It couples the schedule change with a region‑specific rollout plan, acknowledging the North‑East’s unique cultural reliance on herbal tinctures.

Conclusion

The July 2026 amendment to India’s drug‑control schedules represents a decisive step toward curbing the misuse of high‑alcohol medicinal formulations. By moving products that exceed 12 % (v/v) ethanol and 30 mL in volume into the tightly monitored Schedule H1, the Ministry of Health and Family Welfare addresses a documented rise in non‑prescribed consumption, aligns India with international best practices, and creates a regulatory framework that can be scaled to other high‑risk botanical products.

Nevertheless, the policy’s success hinges on several inter‑dependent factors:

• Effective enforcement: State drug‑control agencies must invest in digital tracking and border‑security collaboration to prevent illegal diversion.
• Industry adaptation: Small‑scale manufacturers need technical assistance to reformulate products or meet licensing requirements without jeopardizing livelihoods.
• Public‑education campaigns: Awareness initiatives targeting youth and traditional healers can mitigate the demand side of the problem.
• Regional support mechanisms: Tailored subsidies or tax incentives for low‑alcohol reformulations could accelerate a shift toward safer, non‑intoxicating herbal medicines.

If these conditions are met, the regulatory overhaul could reduce unrecorded alcohol consumption by an estimated 2–3 million litres per year, prevent hundreds of ethanol‑related hospitalisations, and preserve the therapeutic integrity of India’s rich herbal heritage. The North‑East, with its deep-rooted tradition of aromatic medicine, stands as both a proving ground and a potential catalyst for a broader, nationwide transformation in how medicinal alcohol is regulated, produced, and consumed.